Effect of Dexmedetomidine on Inflammatory Response in Aortic Dissection

Objective: To study the effect of dexmedetomidine (Dex) on perioperative inflammatory response in aortic dissection (AD) patients.
Methods: From June 2020 to June 2022, 50 patients with Stanford type B AD underwent endovascular stent-graft exclusion (EVAR) at our hospital. They randomly were assigned to two groups (N = 25): the control group (C group) and the Dex group. Patients in the Dex group received 0.5ug/kg Dex intravenously 10 minutes before induction of anesthesia and 0.5µg/kg/h Dex during the intervention until 15 minutes before the end of surgery. In contrast, the C group received the same volume of normal saline at the same time points. The two groups were induced and maintained with the same anesthetic agents. Venous blood samples were taken 3 days before operation (T1), 1 day before operation (T2), 1 day after operation (T3) and 3 days after operation (T4) to detect levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count (WBC).
Results: At T3 and T4, CRP and ESR in the Dex group were significantly improved compared with those in the C group.
Conclusion: Dexmedetomidine can reduce the inflammatory reaction of aortic dissection.